Real-World Treatment Study of Soliris (Eculizumab) - SolirisPMS

Study identifier:D7412R00001

ClinicalTrials.gov identifier:NCT06448715

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Real-World Treatment Study of Soliris (Eculizumab)

Medical condition

observational

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

11

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 28 May 2024
Estimated Primary Completion Date: 17 Oct 2024
Estimated Study Completion Date: 17 Oct 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria